Navigation Links
Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases

nflammatory diseases aligns seamlessly with Xencor's pipeline development," said Bassil Dahiyat, Ph.D., chief executive officer of Xencor. "We expect that XmAb5871 will soon become the fifth XmAb-engineered antibody in clinical development.  This program is a testament to the progress we've made expanding the XmAb platform into autoimmune disease with our CD32b technology, which is at the core of the XmAb5871 compound. The option deal structure allows us to continue to lead the development of XmAb5871 while also leveraging Amgen's experience in developing novel biologics for unmet medical needs."  

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit  

About XencorXencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates into the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, an anti-CD30 candidate XmAb®2513 which completed a Phase 1 clinical trial for the treatment of Hodgkin's

Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Call for Applications: The Amgen Award for Science Teaching Excellence
2. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
3. Amgen to Provide Testimony at FDA Hearing on Biosimilars
4. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
5. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
6. Array BioPharma and Amgen Partner in Type 2 Diabetes
7. Amgen to Present at Lazard Capital Healthcare Conference
8. Amgen Announces Webcast of 2009 Third Quarter Financial Results
9. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
10. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Post Your Comments:
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... oncology company developing new treatments for cancer and ... Chief Executive Officer, will be presenting at the ... Las Vegas :Event:Aegis Capital Corporation 2015 ... PDTLocation:Brahms 2 room, The Encore @ The Wynn ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, today announced its schedule ... place in the month of October: Stem ... RepliCel will be presenting at the annual Partnering Forum, ... to be held October 7-9 in La ...
Breaking Biology Technology:
... sole U.S. supplier of 3M electrosurgical grounding pads ... ... Industries, Inc. and,3M Health Care announce an exclusive license and supply ... agreement,Medline has acquired the exclusive license and sales rights in the ...
... Eastern Time Today, GAITHERSBURG, Md., March 6 ... and corporate progress for,the full year ended December 31, ... further demonstrated that Iomai,s,vaccine and immunostimulant patches can be ... chief executive officer,of Iomai. "This lays the foundation for ...
... (Pink Sheets: VXGN), a biopharmaceutical company, today reported its,year ... a view to,ensuring that stockholders have the most current ... with Raven biotechnologies,inc. VaxGen,s Board of Directors has set ... of Stockholders to vote on the proposed merger., ...
Cached Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The global glucose monitoring device ... 2015. So says a new report on the industry from ... segment dominate the market, followed by continuous glucose monitoring and ... on the market for these products in its latest report, ... , ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):
... and Nanosystems Research (IBN), Austrian Academy of Sciences ... of Technology, Cambridge, USA report the study of ... Designer Lipid-Like Peptide Surfactants” in the May 30th ... Their findings not only help us to ...
... a chronic and progressive lung disorder from which most patients ... by the insidious onset of dyspnea or cough and usually ... coworkers present in an article published in the online, open-access ... that a subset of IPF patients has a short duration ...
... chronic lung disease typically characterized by the slow but ... patients live about five years after diagnosis. However, according ... online journal PLoS ONE, a subset of patients with ... progression to complete pulmonary failure and death without a ...
Cached Biology News: